Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 3,2213,240 of 20,252 grants

Completed TRAINING, INDIVIDUAL
Targeting Nonsense-Mediated RNA Decay in Splicing Factor Mutant Myeloid Malignancies.
NATIONAL CANCER INSTITUTE Washington University United States 2023 – 2025

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by peripheral blood cytopenias, bone marrow dysplasia, and ineff...

$349.3K
USD
Completed NON-SBIR/STTR RPGS
Targeting pancreatic cancer's metabolic addiction to HuR
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2023 – 2025

Pancreatic ductal adenocarcinoma (PDA) is the 3rd leading cause of cancer death in the U.S. and is generally refractory to chemotherapy. We discovered that the harsh PDA microenvir...

$4.18M
USD
Active RESEARCH CENTERS
HCC Ovarian Cancer SPORE
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT – OVERALL Ovarian cancer (OvCa) has the third highest mortality to incidence ratio and is the fifth leading cause of cancer death in American women. The ty...

$21.65M
USD
Active RESEARCH CENTERS
Administrative Core
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT – CORE A The HCC OvCa SPORE Administrative Core (Core A) is co-directed by SPORE PIs Ronald Buckanovich, MD, PhD and Robert Edwards, MD. Core A will (i) pr...

Active RESEARCH CENTERS
Project 1: EZH2 Inhibition to Prevent/Overcome Chemoresistance
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

ABSTRACT – PROJECT 1 The ability to overcome the development of chemotherapy resistance and maintain sensitivity to the most effective chemotherapy in ovarian cancer, platinum, is...

Active RESEARCH CENTERS
Project 2: Combination PARPi-BETi to Overcome PARPi Resistance
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

ABSTRACT – PROJECT 2 PARP inhibitors have emerged as an established standard of care option in epithelial ovarian cancer (OvCa). Approximately half of OvCa patients harbor inactiva...

Active RESEARCH CENTERS
Project 3: Hedgehog Inhibition to Enhance Response to ICI Therapy
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

SUMMARY/ABSTRACT – PROJECT 3 When effective, immune checkpoint inhibitor (ICI) therapy can significantly improve the outcome of patients with ovarian cancer (OvCa). However, only 1...

Active RESEARCH CENTERS
Core B: TCP: Translational Pathology Core
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY – TRANSLATIONAL PATHOLOGY CORE The high case-fatality of ovarian cancer makes translational studies essential for advancing treatment and improving outcomes. The Hi...

Active RESEARCH CENTERS
Core C: BBC: Biostats and Bioinformatics Core
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY – BIOSTATISTICS/BIOINFORMATICS CORE The Biostatistics/Bioinformatics Core of the Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE provides services for the d...

Active RESEARCH CENTERS
DRP: Developmental Research Program
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY – DEVELOPMENTAL RESEARCH PROGRAM (DRP) The Developmental Research Program (DRP) of the UPMC Hillman Cancer Center (HCC) Ovarian Cancer SPORE seeks to fund and facil...

Active RESEARCH CENTERS
CEP: Career Enhancement Program
NATIONAL CANCER INSTITUTE University of Pittsburgh At Pittsburgh United States 2023 – 2028

PROJECT SUMMARY – CAREER ENHANCEMENT PROGRAM (CEP) The mission of the Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE Career Enhancement Program (CEP) is to foster the deve...

Active RESEARCH CENTERS
Kaposi Sarcoma in the Era of ART in Africa Program (KEAAP)
NATIONAL CANCER INSTITUTE Lsu Health Sciences Center United States 2023 – 2028

There are currently over 1.2 million people in Zambia and 1.7 million in Tanzania who are living with HIV/AIDS. Concomitant to the HIV epidemic, there is a high incidence of HIV/AI...

$1.25M
USD
Active OTHER RESEARCH-RELATED
Regulation of Genome Stability and Structure by the Nucleosome Remodeler HELLS in Leukemia
NATIONAL CANCER INSTITUTE Rockefeller University United States 2023 – 2027

Project Summary/Abstract Eukaryotic cells require the tight regulation of global gene expression to maintain homeostasis and respond to environmental stimuli. DNA spools around his...

$1.15M
USD
Active NON-SBIR/STTR RPGS
Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer
NATIONAL CANCER INSTITUTE University of Georgia United States 2023 – 2027

PROJECT SUMMARY: For women in the United States, breast cancer is the most common malignancy and the second leading cause of death. In this application, we focus upon a specific su...

$10
USD
Active NON-SBIR/STTR RPGS
Southern Environmental Health Study
NATIONAL CANCER INSTITUTE Vanderbilt University Medical Center United States 2023 – 2027

SUMMARY Approximately 80% of human cancers are caused by adverse environmental exposures, unhealthy lifestyles and/or their interactions with host susceptibility factors. Previous...

$25.51M
USD
Active TRAINING, INDIVIDUAL
The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
NATIONAL CANCER INSTITUTE Ohio State University United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT The 5-year overall survival rate for acute myeloid leukemia (AML) is less than 35%, making it the most fatal leukemia in adults. Natural killer (NK) cells...

$432.9K
USD
Active TRAINING, INDIVIDUAL
Investigating tRNA biology as a prognostic and oncogenic feature in pancreatic adenocarcinoma
NATIONAL CANCER INSTITUTE Johns Hopkins University United States 2023 – 2026

PROJECT SUMMARY Pancreatic ductal adenocarcinoma (PDAC) is uniquely difficult to treat due to late diagnosis and limited medical management options for a majority of patients. This...

$539.7K
USD
Active NON-SBIR/STTR RPGS
Multiscale modeling of spatiotemporal evolution in Barrett's esophagus
NATIONAL CANCER INSTITUTE University of California, San Diego United States 2023 – 2028

PROJECT SUMMARY The practical goal of this project is to obtain high-resolution genetic and epigenetic maps that reveal the evolutionary relationships and dynamics over space and t...

$5.51M
USD
Active TRAINING, INDIVIDUAL
Mechanisms of pathogenic gene activation by aberrant transcriptional hubs formed by mutant ENL
NATIONAL CANCER INSTITUTE University of Pennsylvania United States 2023 – 2026

PROJECT SUMMARY Transcription is an essential and tightly regulated process that requires the coordination of many factors to ensure proper gene expression. Current models of trans...

$489.7K
USD
Active TRAINING, INDIVIDUAL
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2023 – 2027

PROJECT SUMMARY/ABSTRACT Sacrococcygeal teratomas (SCTs) are the most common tumor in newborns, have significant perinatal morbidity and mortality, a 35% rate of recurrence, and la...

$410.8K
USD